SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists

CareDx, Inc. (NASDAQ:CDNA)

US · Delayed Price · Currency is USD
62.29-0.75 (-1.19%)
 
Market Cap3.22B+321.2%
Revenue (ttm)458.09M+34.4%
Net Income111.01M+114.8%
EPS2.07+103.1%
Shares Out51.73M
PE Ratio28.95
Forward PE48.29
Dividendn/a
Ex-Dividend Daten/a
Volume449,772.856
Open61.40
Previous Close63.04
Day's Range61.19 - 63.23
52-Week Range13.95 - 72.51
Beta2.38
AnalystsBuy
Price Target62.25(-0.06%)
Earnings DateNov 3, 2026
-1.00% (1D)
No price history available.
Insider Score
––Not scored
CDNA Insider Score

Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.

About CDNA

CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.

Address
8000 Marina Boulevard, Brisbane, CA, 94005, US
Market Cap
3.22 billion
Employees
763
Industrial Classification
Medical - Diagnostics & Research

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$11.00M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

1 Day
-1.19%
5 Days
-6.09%
1 Month
+23.81%
6 Months
+247.60%
1 Year
+321.16%

$CDNA stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in CDNA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by CDNA's directors and management

Net Shares Purchased by Insiders−300k−150k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

CDNA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

CDNA Revenue by Segment or Geography

CDNA's latest filing doesn't break out revenue by segment.

As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New CDNA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to CDNA from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in CDNA

ETFEst. Holding Size
ARKGARK Genomic Revolution ETF$90.65M
XBIState Street SPDR S&P Biotech ETF$88.28M
IWMiShares Russell 2000 ETF$85.00M
VTIVanguard Morningstar Total Stock Market ETF$77.99M
IWOiShares Russell 2000 Growth ETF$30.25M
VXFVanguard Extended Market ETF$30.10M

Estimated from each fund’s disclosed top holdings × AUM

CDNA Insider Score

Our composite score: insider buying, sector, volume, tone & dilution

Members only

The live Insider Score for CDNA is included with Insider Access.

Unlock Insider Score

Bull Case vs Bear Case

AI-generated from CDNA’s recent data — informational, not investment advice

Generating analysis…

Insider Score

Our 0–100 Insider Score and the signals behind it.

Members only

The live Insider Score and its full factor breakdown are included with Insider Access.

Unlock Insider Score

Recent Insider Activity

Buys
0
Sells
12
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.
CareDx, Inc. (CDNA) Insider Trading, Form 4 Buys & Sells | InsiderBuying.com